Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1834 • ACR Convergence 2020
Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus
Ashley Orillion¹, Loqmane Seridi¹, Matteo Cesaroni², Jessica Schreiter¹, Jacqueline Benson³, William Stohl⁴, Walter Winn Chatham⁵, Richard Alan Furie⁶, Thi-Sau Migone⁷, Stanley Marciniak¹, Zhenling Yao¹, Bhaskar Srivastava¹, Marc Chevrier² and Jarrat Jordan¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, ³Janssen Research & Development, LLC, South San Francisco, CA, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁷Independent Consultant, Spring House
Background/Purpose: JNJ-839 is a fully human neutralizing antibody selective to human IFN-ω and IFN-α subtypes. Here we report the exploratory biomarker analyses of a Phase…
Abstract Number: 1986 • ACR Convergence 2020
Determinants of Variation in Pediatric Systemic Lupus Erythematosus Care Delivery
Jon Burnham¹, Rosemary Peterson¹, Joy Ukaigwe¹, Lynsey Cecere¹, Andrea Knight² and Joyce Chang¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with pediatric systemic lupus erythematosus (pSLE) receive only a fraction of recommended care. Moreover, variation in care delivery likely contributes to pervasive racial…
Abstract Number: 0045 • ACR Convergence 2020
Healthcare Practitioner Confidence Assessing Rashes in Patients of Skin of Color with Lupus
Vijay Kannuthurai¹, Jacob Murray², Lisa Zickuhr³ and Ling Chen², ¹Washington University in St. Louis School of Medicine, Hazlehurst, MS, ²Washington University in St. Louis School of Medicine, St. Louis, MO, ³Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Medical education can promote bias that disproportionately affects patients of color. Patients of color with lupus are especially vulnerable as they often carry a…
Abstract Number: 0255 • ACR Convergence 2020
Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint
Vera Golder¹, Rangi Kandane-Rathnayake¹, Molla Huq², Worawit Louthrenoo³, Shue Fen Luo⁴, Yeong-Jian Wu⁵, Aisha Lateef⁶, Sargunan Sockalingam⁷, Sandra Navarra⁸, Leonid Zamora⁹, Laniyati Hamijoyo¹⁰, Yasuhiro Katsumata¹¹, Masayoshi Harigai¹², Madelynn Chan¹³, Sean O'Neill¹⁴, Fiona Goldblatt¹⁵, Chak Sing Lau¹⁶, Zhanguo Li¹⁷, Alberta Hoi¹⁸, Mandana Nikpour¹⁹ and Eric Morand²⁰, ¹Monash University, Clayton, Victoria, Australia, ²University of Melbourne, Melbourne, Victoria, Australia, ³Maharaj Nakorn Chiangmai, Muang, Thailand, ⁴Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Thomas, Manila, Philippines, ¹⁰University of Padjadjaran, Bandung, Indonesia, ¹¹Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴Sydney University, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Hong Kong University, Hong Kong, Hong Kong, ¹⁷Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ¹⁸Monash University, Melbourne, Victoria, Australia, ¹⁹The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, ²⁰Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) has recently undergone prospective longitudinal validation in a multinational cohort, demonstrating the association of attaining LLDAS with…
Abstract Number: 0272 • ACR Convergence 2020
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
Eric Morand¹, Vera Golder², Worawit Louthrenoo³, Shue Fen Luo⁴, Yeong-Jian Wu⁵, Aisha Lateef⁶, Sargunan Sockalingam⁷, Sandra Navarra⁸, Leonid Zamora⁹, Laniyati Hamijoyo¹⁰, Yasuhiro Katsumata¹¹, Masayoshi Harigai¹², Madelynn Chan¹³, Sean O'Neill¹⁴, Fiona Goldblatt¹⁵, Yi-Hsing Chen¹⁶, Yanjie Hao¹⁷, Zhuoli Zhang¹⁷, Jun Kikuchi¹⁸, Tsutomu Takeuchi¹⁹, Chak Sing Lau²⁰, Zhanguo Li²¹, Alberta Hoi²², Mandana Nikpour²³ and Rangi Kandane-Rathnayake², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Monash University, Clayton, Victoria, Australia, ³Chiang Mai University Hospital, Muang, Thailand, ⁴Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Thomas, Manila, Philippines, ¹⁰University of Padjadjaran, Bandung, Indonesia, ¹¹Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴Sydney University, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹⁷Peking University First Hospital, Beijing, China (People's Republic), ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁹Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ²⁰Hong Kong University, Hong Kong, Hong Kong, ²¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ²²Monash University, Melbourne, Victoria, Australia, ²³The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…
Abstract Number: 0290 • ACR Convergence 2020
Role of Protein Tyrosine Phosphatase 1B (PTP1B) in Endothelial-to-Mesenchymal Transition (EndoMT) Promoted by Inflammation: Implications for SLE
Jorge Romo-Tena¹, José Esparza-López², Carmelo Carmona-Rivera³, Luz Blanco⁴, Mariana Kaplan³ and María de Jesús Ibarra-Sánchez², ¹NIAMS, National Institute of Health, Bethesda, ²INNSZ / UNAM-RAI, Mexico City, Mexico, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville
Background/Purpose: The endothelial-to-mesenchymal transition (EndoMT) transdifferentiation process can be promoted by several proinflammatory mediators in many pathological conditions. Recently, it was suggested a crucial role…
Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Elizabeth Park¹, Jon Giles², Thania Perez-Recio¹, Paloma Pina³, Christopher Depender¹, Joan Bathon¹ and Laura Geraldino-Pardilla⁴, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY, ³Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
Abstract Number: 0529 • ACR Convergence 2020
A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
Savino Sciascia¹, Massimo Radin¹, Irene Cecchi¹, Daniela Rossi¹ and Dario Roccatello², ¹University of Torino, Torino, Italy, ²S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Prospective data confirming the role of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in the absence of other aPL tested by β2–glycoprotein I-depend assays are missing.Methods: Since 2015 aPSPT…
Abstract Number: 0836 • ACR Convergence 2020
SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus
Tomoyuki Mukai¹, Kyoko Kawahara¹, Masanori Iseki², Akiko Nagasu¹, Hajime Nagasu³, Takahiko Akagi¹, Shoko Tsuji¹, Yasuyoshi Ueki⁴, Katsuhiko Ishihara², Naoki Kashihara³ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN
Background/Purpose: The adaptor protein, Src homology 3 domain-binding protein 2 (SH3BP2), is widely expressed in immune cells, such as myeloid cells, B cells, and T…
Abstract Number: 0856 • ACR Convergence 2020
Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels
Michelle Petri¹ and Jessica Li², ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) dosing is reduced in those with renal insufficiency according to guidelines (Marmor MF, et al. Ophthalmology 2016;123:1386–94) as it is partially cleared…
Abstract Number: 0935 • ACR Convergence 2020
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in SLE
Richard Furie¹, Ronald van Vollenhoven², Kenneth Kalunian³, Sandra Navarra⁴, Juanita Romero-Díaz⁵, Victoria Werth⁶, Xiaobi Huang⁷, Hua Carroll⁸, Adam Meyers⁷, Cristina Musselli⁷, Catherine Barbey⁹ and Nathalie Franchimont⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³University of California San Diego, La Jolla, CA, ⁴University of Santo Tomas, Manila, Philippines, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁶University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁷Biogen, Cambridge, MA, ⁸Biogen, Cambridge, ⁹Biogen, Baar, Switzerland
Background/Purpose: Type I interferons (IFN-I), inflammatory mediators principally produced by plasmacytoid dendritic cells (pDCs), components of the innate immune system, have been implicated in the…
Abstract Number: 0992 • ACR Convergence 2020
Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment
Neha Nandedkar-Kulkarni¹, Nida Meednu², Jennifer Albrecht², Jennifer Barnas², Douglas Widman³ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells play a key…
Abstract Number: 1145 • ACR Convergence 2020
Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study
Shanthini Kasturi¹, Lori Lyn Price¹, David Curtis², William Nowell³, Norma Terrin¹, Jane Salmon⁴, Lisa Mandl⁴ and Timothy McAlindon¹, ¹Tufts Medical Center, Boston, MA, ²Global Healthy Living Foundation, New York City, ³Global Healthy Living Foundation, New York City, NY, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Patient-reported outcome measures (PROMs) are powerful tools which can highlight the patient experience of illness. Although PROMs are standard metrics in SLE clinical research,…
Abstract Number: 1271 • ACR Convergence 2020
Post-Traumatic Stress Disorder (PTSD) and Risk of Systemic Lupus Erythematosus (SLE) Among Medicaid Recipients
Siobhan Case¹, Candace Feldman¹, Hongshu Guan¹, Laura Kubzansky², Karestan Koenan² and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Post-traumatic stress disorder (PTSD), the sentinel stress-related mental disorder, may be associated with increased risk of developing autoimmune disease, including systemic lupus erythematosus (SLE).…
Abstract Number: 1287 • ACR Convergence 2020
Prevalence of Morbidity Prior to Diagnosis of Incident Systemic Lupus Erythematosus in the Danish Population
Julia Simard¹, Mikkel Faurschou², Soeren Jacobsen² and Renata Hansen², ¹Stanford Medicine, Stanford, CA, ²Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark
Background/Purpose: Patients with SLE experience a high burden of various comorbidities at disease onset and during disease progression. Studies of excess morbidity prior to SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].